



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Eidgenössische Kommission für Drogenfragen
Commission fédérale pour les questions liées aux drogues
Commissione federale per le questioni relative alla droga

Rechtliche und politische Situation

-

Position der Eidgenössischen Kommission für Drogenfragen EKDF


Tagung 22.1.2013, Universität Bern
Cannabinoide in der Medizin – Eine Option?

Dr. med. Toni Berthel
Eidg. Kommission für Drogenfragen EKDF




1. Context, History

- **1951** Swiss Narcotics Law (Repression, Prevention)
- **1975** Revision of the Narcotics Law (Repression, Prevention, Therapy)
- **1990s** Fourfold model, HAT (Repression, Prevention, Therapy, Harm Reduction)
- **2011** 2nd Revision of the Narcotic Law (Four Pillar Model and HAT)





Würfelmodell 2004





- Future Measures in Drug Policy must attend:
(EKDF 2011)
 - Distinction between low-risk, problematic and addictive consumption
 - Risk-avoidance for third persons
 - Orientation to possible individual and collective harms
 - Orientation to the riskiness of the substances
 - Law enforcement and market regulation influence supply and demand
 - Regulation intensity is determined by the riskiness of the substances



The EKDF's Position concerning Cannabis

- Consumption is generally unproblematic (adults)
- Impunity of unproblematic consumption
- No penalty for addicted persons
- Equal treatment as towards the consumption of alcohol and tobacco
- Protection of minors / young people



Policyfields EKDF: Cannabis

- Cannabis regulatory models
- Use of hemp and further substances in medicine
- Cannabis médical, expérimentation „modélées“
- Research fields
 - Monitoring
 - Market development Cannabis
 - Substance
- Regulatory questions Cannabis
 - Not concerning small amounts
 - Impunity of consumption and possession



Legislation Goals EKDF

- Cannabis médical
 - EKDF gets informed about the current practical experiences on Cannabis médical, evaluates the compliance of the current regulations and potentially suggests new regulations on the field



Medical use of Cannabinoids

Goals of the EKDF

- A medically reasonable application, under the current regulation of exceptional permissions, is illegal or takes place in a legal gray area. The commission is considering the limits of the legal indication as too narrow.
- Various Studies and Reports indicate, that the authorized pharmaceuticals don't reach the same results as the application of the cannabis plant. This might push the patients towards the legal gray area.
- The Commission pleads for the authorization of further pharmaceuticals as the currently listened, and their registration at the compulsory health insurance.



EKDF's Goals on Cannabis médical

- Wider Indications for the medical use of Cannabis
- Pharmaceuticals containing Cannabis vs. Cannabis as a plant
- Authorization of further pharmaceuticals



Schweizerische Eidgenossenschaft
Confédération suisse
Confederazione Svizzera
Confederaziun svizra

Eidgenössische Kommission für Drogenfragen
Commission fédérale pour les questions liées aux drogues
Commissione federale per le questioni relative alla droga

- Thank you for your Attention